Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (156)	9/19/2007 4:58:10 PM
From: Mike McFarland	Respond to of 210

First of all, I guess this is my accounting answer for Deferred Long Term Liability Charges $57M --looks like nothing all that interesting. In February 2007, the Emerging Issues Task Force of the FASB issued EITF 07-3, “ Accounting for Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development Activities ” (“EITF 07-3”). In EITF 07-3, the task force reached a consensus that nonrefundable advance payments for goods or services to be received in the future for use in research and development activities should be deferred and capitalized. The capitalized amounts should be expensed as the related goods are delivered or the services are performed. EITF 07-3 is effective for new contracts entered into during fiscal years beginning after December 15, 2007, including interim periods within those fiscal years. We have not completed our evaluation of EITF 07-3, but we do not currently believe it will have a material impact on our results of operations or financial position. ---------------------------- If you got some shares this afternoon around $8.65 that was a pretty good trick, but I ain't buyin nuthin. I did swap a little of our glgc back into tgen after the RAC news--but most of my cash is locked up so I can't hurt myself. I wont be able to buy back any INFI til next spring even if I wanted to--and if I'm smart I'll just roll over the CD into a new one. Gotta say, when you go to the SEC filings and see Holtzman with another 5000 shares, on top of the 200,000 some odd shares he has, you see the truth of it all--If you wanna get rich in biotech, dorking around with a few thousand shares here and there isn't the way to do it. What you gotta do is start your own company <g> (Or bet really big, get lucky, and let it run). Now those 200k shares, hey, not a big deal, a couple of million worth. And that level of compensation does not strike me as being excessive at all. But I do lose interest in buying 1000 or 2000 shares for myself. Why do it, it is peanuts. Likewise, my pathetic little bet on tgen--just novelty shares. No way to make any real money with small bets, and I am too risk averse to bet big. And my stock picking stinks, ha!